A 52 Week Open-Label Extension Study of the Long-Term Safety and Efficacy of Rosiglitazone Extended-Release (RSG XR) as Adjunctive Therapy to Acetylcholinesterase Inhibitors in Subjects with Mild-to-Moderate Alzheimer’s Disease (REFLECT-4), GlaxoSmithKline.